刘东红;

• 1:北京市药品监督管理局东城分局 北京市100007

摘要(Abstract)：

目的:源于上世纪初的微生物理论而于近年发展的微生态制剂在临床上广泛应用,借以调整微生态失调,保持生态平衡,促进内环境的稳定,控制某些感染性、菌群生态失调、菌群定位转移所相关的多种胃肠道疾病。本文剖析此类药物的分类、作用、评价和应用原则,为临床提供较为丰厚的信息。方法:综述国内外医药学文献。结果及结论:鉴于微生态制剂上市历程尚短,对其药动学、体内过程、临床疗效等参数,迄今为止的报道甚少,尚有待于循证医学的多中心、大样本的研究结果所证实。

关键词(KeyWords)： 微生态制剂;益生菌;腹泻;肠应激综合征;进展

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 刘东红;

DOI: 10.14009/j.issn.1672-2124.2006.03.004

参考文献(References)：

• [1]Salminen S,Arvilommi H.Probiotic demonstrating efficacy in clinical setting[J].Clin Infrct Dis,2001,32(6):1577.
• [2]Saavedra JM.Clinical application of probiotic agents[J].AmJ Clin Nutr,2001,73(suppl):1147.
• [3]Karen Madsen,Anthony Cornish,Paul Soper,et al.Probiotic bacteria enhancemurine and humanintestinal epithelial barrier function[J].Gastroentrology,2001,121(3):580.
• [4]Erika Isolauri.Probiotics in human disease[J].Am J Clin Nutr,2001,73(suppl):1142S.
• [5]Flynn S,Van Sinderen D,Thornton GM,et al.Characterization of the genetic locus responsible for the production of ABP-118,a novel bacteriocin produced bytheprobiotic bacterium lactobacillus salivarius subsp salivarius UCC118[J].Microbiology,2002,148(4):973.
• [6]Dunne C,L Murphy,S Flynn,et al.Probiotics from myth to reality.Demonstration of functionality in animal models of disease and in human clinical trials[J].Antonie Van Leeuwenhoek,1999,76:279.
• [7]Guandalini S,Pensabene L,Zikri MA,et al.Lactobacillus GG administeredin oral rehydration solutionto children with acute diarrhea:a multicenter European trial[J].J Pediatr Gast roenterol Nutr,2000,30(2):214.
• [8]黄培宁.双岐三联活菌制剂治疗霉菌性肠炎68例[J].海南医学,2004,15(3):37.
• [9]Aloysius L DSouza,Chakravarthi Rajkumar,Jonathan Cooke,et al.Probiotics in prevention of antibiotic associated diarrhoea:meta-analysis[J].ΒMJ,2002,324:1361.
• [10]珺耀,赵锋.3种微生态制剂与常用抗菌药物的相互作用[J].中国医院药学杂志,2003,23(7):419.
• [11]潘国宗,鲁素彩,柯美云,等.北京地区肠易激综合征的流行病学研究[J].北京医学杂志,2000,21(1):26.
• [12]Prmenmtel M,Eyely J,Chow BA,et al.Eradication of mall intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome[J].AmJ Gastroenterol,2000,95:3503.
• [13]Niedzielin K,Kordecki H,Birkenfeld B.Acontrolled,double-blind,randomized study on the efficacy of lactobacillus plantarum299vin patients withirritable bowel syndrome[J].Eur J Gastroenterol Hepatol,2001,13:1143.
• [14]Linskens PK,Huijsdens XW,Savelkoul PH,et al.The bacterialflora in inflammatory bowel disease:current insights in pathogenesis and the influence of antibiotics and probiotics[J].ScandJ Gastroenterol,2001,(234Suppl):S29.
• [15]Guslandi M,Mezzi G,Sorghi M,et al.Saccharomyces boulardii in maintenance treatment of Crohn s disease[J].Dig Dis Sci,2000,45(7):1462.
• [16]Rembacken BJ,Snelling AM,Hawkey PM,et al.Nonpathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis:a randomized trial[J].Lancet,1999,354(9194):2000.
• [17]Aiba Y,Suzuki N,Kabir AM,et al.Lactic acid-mediated suppression ofHelicobacter pyloribythe oral administration of Lactobacill us salivari usas a probiotic in a gnotobiotic murinemodel[J].AmJ Gastroenterol,1998,93:2097.
• [18]Armuzzi A,Cremonini F,Bartolozzi F,et al.The effect of oral administration of lactobacillus GG on anti-bioticassociated gas trointestinal sideeffects duringHelicobacter pylori eradication therapy[J].Aliment Pharmacol Ther,2001,15(2):163.
• [19]李瑞军,杨徐昭.微生态制剂在消化系统疾病中的应用进展[J].中国新药杂志,2003,12(6):416.
• [20]Wollowski I,Rechkemmer G,Pool-Zobel BL.Protective role of probiotics and prebiotics in colon cancer[J].Am J Clin Nutr,2001,73:451S.
• [21]卜淑蕊,关志明,闫柱.调整肠道菌群对肝硬化大鼠肝组织学的影响[J].中国微生态学杂志,2001,13(2):83.
• [22]钱康年.微生态制剂的临床应用情况[J].中国医师杂志,2002,4(2):122.